Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00920855 · ClinicalTrials.gov registry record · Phase 1
Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma
A Phase 1 study of Multiple Myeloma, sponsored by Cephalon.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 13
- Study locations
NCT00920855 is a Phase 1 study of Multiple Myeloma that has completed, run by Cephalon. The registered enrollment target is 40 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The trial reports 13 study locations across 9 states.
The verdict
NCT00920855, a Phase 1 study of Multiple Myeloma, has completed, sponsored by Cephalon.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 13
- Study locations
Study Summary
The primary objective of this study is to assess the safety and tolerability of bendamustine as combination therapy with bortezomib for patients with relapsed/refractory multiple myeloma (MM).
Conditions Studied
Interventions
- DRUG bendamustine
- DRUG bortezomib
Study Locations (13)
California
- Pacific Oncololgy & Hematology - Encinitas
- Capitol Hematology Oncology - Roseville
- University Of California, San Diego - San Diego
- James R. Berenson, M.D., Inc. - West Hollywood
Maryland
- Alivin & Lois Lapidus Cancer Institute - Baltimore
- Center for Cancer and Blood Disorders - Bethesda
District of Columbia
- George Washington University - Washington D.C.
Illinois
- Northshore University Health System - Evanston
Massachusetts
- Sophia Gordon Cancer Center at Lahey Clinic - Burlington
Pennsylvania
- Geisinger Medical Center - Danville
South Carolina
- Charleston Hematology Oncology, PA - Charleston
Tennessee
- Family Cancer Center, PLLC - Collierville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00920855
The ClinicalTrials.gov registry entry for NCT00920855 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (93% lower). The listed sponsor is Cephalon, which has 64 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which bendamustine is the first listed.
NCT00920855 reports 13 study locations spanning 9 distinct geographic areas - top geographies include California, Maryland, District of Columbia.
Frequently Asked Questions
What is clinical trial NCT00920855 about?
NCT00920855 is a clinical study titled "Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma". The primary objective of this study is to assess the safety and tolerability of bendamustine as combination therapy with bortezomib for patients with relapsed/refractory multiple myeloma (MM).
What is the current status of trial NCT00920855?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2009-06. Estimated completion is 2011-12.
What conditions does trial NCT00920855 study?
This clinical trial studies the following conditions: Multiple Myeloma.
What interventions are being tested in trial NCT00920855?
The interventions under investigation include: bendamustine (DRUG), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00920855?
This trial is sponsored by Cephalon, which has 64 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00920855 being conducted?
This trial has 13 study locations across California, District of Columbia, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
RECRUITING · Phase 1
-
TriPRIL CAR T Cells in Multiple Myeloma
RECRUITING · Phase 1
-
A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)
RECRUITING · Phase 1
-
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory Multiple Myeloma
RECRUITING · Phase 1
-
Study of Carfilzomib, Lenalidomide, Dexamethasone and Belantamab Mafodotin in Multiple Myeloma
RECRUITING · Phase 1
-
CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.